Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2024-03-04 00:00:00 ET · period of report 2024-02-29 · accession 0001415889-24-006428 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-04 | 2024-02-29 | JANX | Avalon Ventures XI, L.P. | 10% | J - Other | $0.00 | -438.7K | 3.95M | -10% | $0 | |
| MI | 2024-03-04 | 2024-02-29 | JANX | Avalon Ventures XI, L.P. | 10% | J - Other | $0.00 | -532.9K | 4.03M | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-29 | J | D | 438,722 | $0.00 | 3,948,495 | D | — | — | (F2) The shares are held directly by Avalon Ventures. Avalon Ventures XI GP, LLC (Avalon XI GP) is the general partner of Avalon Ventures and may be deemed to beneficially own the shares held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 2 | Common | Common Stock | 2024-02-29 | J | D | 1,700 | $0.00 | 0 | I By Avalon BioVentures GP LLC | — | — | (F14) The shares are held directly by ABV GP. ABV GP is the general partner of ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 3 | Common | Common Stock | 2024-02-29 | J | A | 1,700 | $0.00 | 1,700 | I By Avalon BioVentures GP LLC | — | — | (F14) The shares are held directly by ABV GP. ABV GP is the general partner of ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 4 | Common | Common Stock | 2024-02-29 | J | D | 84,985 | $0.00 | 764,869 | I By Avalon BioVentures I, LP | — | — | (F12) The shares are held directly by ABV I. Avalon BioVentures GP, LLC (ABV GP) is the general partner of ABV I and may be deemed to beneficially own the shares held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 5 | Common | Common Stock | 2024-02-29 | J | D | 31,456 | $0.00 | 0 | I By ABV SPV I GP LLC | — | — | (F9) The shares are held directly by ABV SPV GP. ABV SPV GP is the general partner of ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 6 | Common | Common Stock | 2024-02-29 | J | A | 31,456 | $0.00 | 31,456 | I By ABV SPV I GP LLC | — | — | (F9) The shares are held directly by ABV SPV GP. ABV SPV GP is the general partner of ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 7 | Common | Common Stock | 2024-02-29 | J | A | 11,388 | $0.00 | 11,388 | I By Avalon Ventures XI GP LLC | — | — | (F4) The shares are held directly by Avalon XI GP. Avalon XI GP is the general partner of Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 8 | Common | Common Stock | 2024-02-29 | J | D | 11,388 | $0.00 | 0 | I By Avalon Ventures XI GP LLC | — | — | (F4) The shares are held directly by Avalon XI GP. Avalon XI GP is the general partner of Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 9 | Common | Common Stock | 2024-02-29 | J | D | 447,949 | $0.00 | 4,031,543 | I By Avalon BioVentures SPV I, LP | — | — | (F7) The shares are directly held by ABV SPV. ABV SPV I GP LLC (ABV SPV GP) is the general partner of ABV SPV and may be deemed to beneficially own the shares held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |